Stockreport

Sunesis Pharmaceuticals Announces Data from Ongoing Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies

SUNESIS PHARMACEUTICALS  (SNSS) 
Last sunesis pharmaceuticals earnings: 3/10 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.sunesis.com/investor-overview
PDF SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced data from the Company’s Phase 1b/2 clinical [Read more]